|
(MoneyNewsWire.Net, January 16, 2014 ) Boston, MA - Shkreli Martin, CEO of Retrophin, Inc. (NASDAQ: RTRX) bought 8,000 shares of Retrophin, Inc. from the open market on 01/14/2014 according to an SEC filing reported by insidercow.com at 01/15/2014 08:00:04 AM ET. The stock was up 5.60% after the InsiderCow.com report.
Trade amount: 8,000 Shares
Trade type: Open Market Buy
Price Range: 11.10 - 12.23
Transaction details can be found at http://www.insidercow.com/history/company.jsp?company=RTRX Get real-time alert on any insider trading information from www.insidercow.com, one step before everybody else.
About InsiderCow.com
InsiderCow.com is a leading real-time insider trading information provider. InsiderCow.com is the online division of InsiderCow, a privately-owned company specialized in insider trading information. InsiderCow uses its proprietary software to gather and analyze information provided by the U.S. Securities and Exchange Commission, in real-time. For more information about InsiderCow.com, visit www.insidercow.com.
About RTRX:
"Retrophin, Inc., a biopharmaceutical company, engages in the discovery,
development, and commercialization of orphan drugs for the treatment of
rare and life-threatening diseases. The company develops treatments for
Focal Segmental Glomerulosclerosis (FSGS), Pantothenate
Kinase-Associated Neurodegeneration (PKAN), Duchenne Muscular Dystrophy
and other catastrophic diseases. Its products include RE-021, a small
molecule angiotensin receptor blocker and selective endothelin receptor
antagonist for the treatment of FSGS; and RE-024, a drug that restores
the disruption in the biochemical Coenzyme A pathway caused by the
non-functioning PANK2 encoded enzyme. The company also develops RE-001, a
recombinant fusion protein that substitutes the dystrophin that is
lacking in DMD patients; and RE-003, an investigational agent for spinal
muscular atrophy. The company was founded in 2011 and is based in New
York, New York."
Disclosure: Insidercow.com is not a registered investment adviser or broker/dealer. Insidercow.com makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable.
InsiderCow
Kevin Leng
781-526-8657
support@insidercow.com
Source: EmailWire.Com 
|
